Clinical Trial Update: Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

View source ↗

Summary

This update indicates that the clinical trial evaluating Certolizumab Pegol for active Rheumatoid arthritis and Crohn's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Rheumatoid Arthritis

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB Pharma | Conditions: Rheumatoid Arthritis, Crohn's Disease | Status: TERMINATED